Genomic Medicine Will Help Shift Cardio Care to Proactive Approach
Genomic medicine will help shift clinical care from reactive to proactive, say the authors.
Hypotension
Raviten Gets Fast Track Status for Intradialytic Hypotension Management
Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.
Ob-Gyns Should Play Role in Reducing CVD Risk for Women
The authors note that most women consider their ob-gyn to be their primary care physician.
Giapreza Now Available to Up BP in Adults With Septic, Other Distributive Shock
Giapreza, a vasoconstrictor, increases blood pressure through increased aldosterone release
Addition of Angiotensin II Improves Mortality in Severe Vasodilatory Shock
Results showed that patients with a baseline APACHE II scores >30 had a significantly improved 28-day mortality trend in the angiotensin II group vs. the placebo group.
Giapreza Approved to Treat Critically Ill Hypotensive Patients
In a clinical trial of 321 patients with shock and a critically low blood pressure, significantly more patients responded to treatment with Giapreza compared to those treated with placebo.
CDC: Heart Disease, Hearing Loss Screening Overlooked for Many Newborns
“Newborn screening at birth is crucial to quickly identify infants at risk of hearing loss and congenital heart disease so they can receive early intervention and follow-up care,” Brenda Fitzgerald, MD, director of the CDC.
Orthostatic Hypotension Guidelines Called into Question
After adjustments, measurement 1 was significantly associated with risk of fall (HR 1.22, 95% CI: 1.03-1.44), fracture (HR 1.16, 95% CI: 1.01-1.34), syncope (HR 1.40, 95% CI: 1.20-1.63), and death (HR 1.36, 95% CI: 1.23-1.51). Measurement 2 was associated with all long-term outcomes, including motor vehicle crashes (HR 1.43, 95% CI: 1.04-1.96).
Angiotensin II Treatment Examined in Vasodilatory Shock
Researchers randomized patients with vasodilatory shock receiving more than 0.2 µg of norepinephrine/kg body weight/minute or equivalent dose of another vasopressor to receive angiotensin II or placebo infusions.
Self-Administered Nasal Spray Examined for Paroxysmal SVT
The researchers found heart rate was controlled within 15 minutes in 87% of patients who received a 70-mg dose of the nasal spray; 75% of patients who got 105-mg; and 95% of patients given a 140-mg dose.
